ArticleBMC pregnancy and childbirth2026
Effect of SARS-CoV-2 infection on pregnant outcomes after embryo transfer: a multicenter retrospective study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
research questionWith the nationwide relaxation of controls for the COVID-19 epidemic from December 2022 in China, fertility and in vitro fertilization (IVF) centers reported increasing numbers of infected patients in a short time. However, there is a lack of information regarding the effects of SARS-CoV-2 infection on pregnancy outcomes after IVF–embryo transfer (ET)/intracytoplasmic sperm injection (ICSI)–ET/frozen–thawed embryo transfer (FET), especially the live birth rate.
designThis multicenter retrospective study was conducted at three public IVF centers in Jiangsu province of China. Women aged 20–42 years who were undergoing IVF–ET/ICSI–ET/FET treatment were consecutively registered from November 23, 2022 to January 7, 2023, with follow-up until October, 2023. Patients during the same period in the previous year were included in the control group. Each woman contributed only one transplantation cycle. Multivariate regression analysis was used to evaluate clinical outcomes primarily between different policy period other than individual infected or not. Covariates included demographic characteristics (age, body mass index (BMI), infertility cause, anti-müllerian hormone (AMH), and Antral Follicle Counting(AFC)) as well as cycle characteristics (treatment protocol, endometrial thickness, number of embryos transferred, and embryonic morphology).
resultsIn this study, we included 779 women in the FET group and 168 women in the IVF–ET/ICSI–ET group, analyze the clinical outcomes of each group separately before and after the relaxation of controls for the COVID-19 epidemic. Pregnancy outcomes, including the clinical pregnancy rate, miscarriage rate, ongoing pregnancy rate, multiple pregnancy rate, and live birth rate, did not change significantly in different policy period. However, the rate of gestational diabetes mellitus (GDM) in FET cycles rather than IVF–ET/ICSI–ET cycles after the relaxation of controls was higher than that 1 year earlier (17.8% vs. 6.8%).
conclusionsThe findings of this study suggest that the relaxation of controls for the COVID-19 epidemic does not have a clear negative effect on the pregnancy outcomes after ET, despite current clinical concerns. Nevertheless, the morbidity of gestational diabetes in FET cycles after the relaxation of controls warrants greater attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.